A new phase-II research project founded at the Danish hospital, Bispebjerg Hospital, aims to bring new knowledge about the effects of medicine based on antibodies in the treatment of severe asthma.
The project, UPSTREAM, involves approximately 40 patients in a randomized and double-blind study. Each patient will receive treatment for 12 weeks with either a placebo or the pharmaceutical candidate, MEDI9929, which is developed in collaboration between Amgen and AstraZeneca.
Contrary to current asthma treatments, which are based on adrenal cortex hormone and affects the entire immune system, MEDI9929 is an antibody and works by inhibiting the specific TSLP protein, which causes asthma attacks, from connecting with its receptor. TSLP is overly active in asthma patients and by blocking the signals in the immune system, asthma attacks can be prevented.
Intially, treatment with MEDI9929 is aimed at patients with severe asthma but eventually the treatment will be available to most asthma patients. The hope is that asthmatics will be able to replace their daily inhaler treatments with a monthly injection of anti-TSLP.
UPSTREAM is financed by the Capital Region of Denmark.